Changes within the biopharma industry have broadened the role of medical affairs and the sphere of stakeholder influence – and importantly, the rise of patient communities as key stakeholders. Indeed, there has been a dramatic shift from looking at patients as subjects, to looking at them as partners, so that now, their input is critical to bringing therapies to market.
In this video, our experts discuss how medical affairs can play a key role in bringing the patient voice into product development, all the way from pre-clinical through to post-marketing and patent expiry.
